依达拉奉治疗韩国肌萎缩侧索硬化症（ALS）患者的效果。
Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
机构信息
Department of Neurology, Dongguk University College of Medicine, Dongguk University Gyeongju Hospital, Gyeongju, South Korea.
Department of Neurology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
出版信息
Neurol Sci. 2020 Jan;41(1):119-123. doi: 10.1007/s10072-019-04055-3. Epub 2019 Aug 30.
Oxidative stress caused by free radicals has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Edaravone (also known as MCI-186), a free radical scavenger, was approved as an ALS treatment in 2015 in Japan. However, the therapeutic effects of edaravone on patients with ALS outside of Japan are not yet reported. This study aims to investigate effects of edaravone on ALS patients in the Korean population. The study included 22 patients with ALS who were treated with edaravone. Of the 16 patients who finished six cycles of treatment, a mean decline of ALSFRS-R after the treatments was 5.75 ± 6.07 points and the average change of FVC was - 8.7 ± 17.0%. Patients experienced only minor adverse events. This study reports on the open-label study of edaravone on patients in Korea for ALS patients, which showed a modest effect of edaravone in this population of ALS patients.
自由基引起的氧化应激与肌萎缩侧索硬化症（ALS）的发病机制有关。依达拉奉（也称为 MCI-186）是一种自由基清除剂，于 2015 年在日本被批准用于 ALS 的治疗。然而，依达拉奉对日本以外的 ALS 患者的治疗效果尚未有报道。本研究旨在探讨依达拉奉对韩国人群中 ALS 患者的影响。该研究纳入了 22 名接受依达拉奉治疗的 ALS 患者。在完成六个周期治疗的 16 名患者中，治疗后 ALSFRS-R 的平均下降值为 5.75±6.07 分，FVC 的平均变化值为-8.7±17.0%。患者仅出现轻微的不良反应。本研究报告了韩国的一项针对 ALS 患者的依达拉奉开放性研究，结果表明依达拉奉对这一人群的 ALS 患者具有一定的疗效。
Zotero 插件